All In Biotech

Drug Trial Radar · NCT01211522

The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study

MIND-USA Study: Modifying the Impact of ICU-Associated Neurological Dysfunction

Last checked: Nov 20, 2026Latest source record: Nov 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 566 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

566

Actual

Start

Dec 14, 2011

Primary completion

Aug 28, 2017

Study completion Jul 19, 2018

Sponsor

Lead sponsor
Vanderbilt University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 29, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The long-term objective of the MIND-USA (Modifying the Impact of ICU-Induced Neurological Dysfunction-USA) Study is to define the role of antipsychotics in the management of delirium in vulnerable critically ill patients. We and others have shown that delirium is an independent predictor of more death, longer stay, higher cost, and long-term cognitive impairment often commensurate with moderate dementia. The rapidly expanding aging ICU population is especially vulnerable to develop delirium, with 7 of 10 medical and surgical ICU patients developing this organ dysfunction. Antipsychotics are the first-line pharmacological agents recommended to treat delirium, and over the past 30 years they gained widespread use in hospitalized patients globally prior to adequate testing of efficacy and safety for this indication. Haloperidol, the most commonly chosen antipsychotic, is used by over 80% of ICU doctors for delirium, while atypical antipsychotics are prescribed by 40%. Antipsychotics safety concerns include lethal cardiac arrhythmias, extrapyramidal symptoms, and the highly publicized increased mortality associated with their use in non-ICU geriatric populations. The overarching hypothesis is that administration of typical and atypical antipsychotics-haloperidol and ziprasidone, in this case-to critically ill patients with delirium will improve short- and long-term clinical outcomes, including days alive without acute brain dysfunction (referred to as delirium/coma-free days or DCFDs) over a 14-day period; 30-day, 90-day, and 1-year survival; ICU length of stay; incidence, severity, and/or duration of long-term neuropsychological dysfunction; and quality of life at 90-day and 1-year. To test these hypotheses, the MIND-USA Study will be a multi-center, double-blind, randomized, placebo-controlled investigation in 561 critically ill, delirious medical/surgical ICU patients who are (a) on mechanical ventilation or non-invasive positive pressure ventilation or (b) in shock on vasopressors. In each group (haloperidol, ziprasidone, and placebo), 187 patients will be enrolled and treated until delirium has resolved for 48 hours or to 14 days (whichever occurs first) and followed for 1 year.

Conditions

  • Delirium
  • Impaired Cognition
  • Long Term Psychologic Disorders

Interventions

  • HaloperidolDrug

    Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.

  • ZiprasidoneDrug

    Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.

  • PlaceboDrug

    Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Delirium/Coma-free Days (DCFDs)Time frame: 14 days

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Denver Health/University of Colorado Health Sciences Center

    Denver, Colorado

  • Yale University Medical Center

    New Haven, Connecticut

  • Indiana University

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Albert Einstein Medical College-Montefiore Medical Center

    The Bronx, New York

  • University of North Carolina - Chapel Hill

    Chapel Hill, North Carolina

  • Moses Cone Health System

    Greensboro, North Carolina

  • The Ohio State Medical Center

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor Health Care System

    Dallas, Texas

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.